LJP 394 tolerance drug targeted to stop production of antibodies to double-stranded DNA: Ended Phase I testing, with no drug-related changes noted, and no adver

La Jolla Pharmaceutical Co.

Read the full 49 word article

How to gain access

Continue reading with a
two-week free trial.